We narrowed to 319 results for: son

#59170-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 7, 2018

Academic Institutions and Nonprofits only

#131004-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE (#131004). In addition to the viral particles, you will also receive purified pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6m and bicistronic ChRmine (red-shifted channelrhodopsin). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

June 4, 2020

Academic Institutions and Nonprofits only

#106180-AAV5

Ready-to-use AAV5 particles produced from pAAV.hSynap-FLEX.SF-iGluSnFR.A184S (#106180). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-iGluSnFR.A184S plasmid DNA. Synapsin-driven, Cre-dependent expression of glutamate sensor iGluSnFR (high affinity). These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

March 19, 2021

Academic Institutions and Nonprofits only

#59170-AAV5

Ready-to-use AAV5 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

July 21, 2017

Academic Institutions and Nonprofits only

#55634-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

May 31, 2019

Academic Institutions and Nonprofits only

#106183-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.A184S (#106183). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.A184S plasmid DNA. Synapsin-driven, Cre-dependent SF-Venus-iGluSnFR.A184S glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Dec. 26, 2018

Academic Institutions and Nonprofits only

#122100-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-GFP (#122100). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-GFP plasmid DNA. EF1a-driven expression of GFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#55638-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#106176-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.S72A (#106176). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.S72A plasmid DNA. hSynapsin driven SF-iGluSnFR.S72A, glutamate sensor. The S72A mutant has lower affinity for glutamate. Slower on-rate and faster off-rate. Enhanced temporal resolution and spatial resolution. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 25, 2019

Academic Institutions and Nonprofits only

#106181-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap-FLEX.SF-iGluSnFR.A184V (#106181). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-iGluSnFR.A184V plasmid DNA. Synapsin-driven, Cre-dependent expression of glutamate sensor iGluSnFR (medium affinity). These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

March 19, 2021

Academic Institutions and Nonprofits only

#106185-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.S72A (#106185). In addition to the viral particles, you will also receive purified pAAV.hSynap-FLEX.SF-Venus-iGluSnFR.S72A plasmid DNA. Synapsin-driven, Cre-dependent SF-Venus-iGluSnFR.S72A glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Dec. 26, 2018

Academic Institutions and Nonprofits only

#55632-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-mCherry-IRES-Cre (#55632). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry-IRES-Cre plasmid DNA. Cre and bicistronic (IRES) mCherry expression under the EF1a promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Aug. 30, 2017

Academic Institutions and Nonprofits only

#51507-AAV5

Ready-to-use AAV5 particles produced from AAV pmSyn1-EBFP-Cre (#51507). In addition to the viral particles, you will also receive purified AAV pmSyn1-EBFP-Cre plasmid DNA. EBFP-Cre expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Oct. 30, 2017

Academic Institutions and Nonprofits only

#55645-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 2, 2019

Academic Institutions and Nonprofits only

#55645-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

June 8, 2020

Academic Institutions and Nonprofits only

#50363-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-DreO-bGHpA (#50363). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-DreO-bGHpA plasmid DNA. hSyn-driven Dre recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Aug. 18, 2020

Academic Institutions and Nonprofits only

#59170-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Chronos-GFP under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Oct. 3, 2017

Academic Institutions and Nonprofits only

#100798-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-FLEX-splitTVA-EGFP-tTA (#100798). In addition to the viral particles, you will also receive purified pAAV-syn-FLEX-splitTVA-EGFP-tTA plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-TREtight-mTagBFP2-B19G (Addgene#100799). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#100799-AAV1

Ready-to-use AAV1 particles produced from pAAV-TREtight-mTagBFP2-B19G (#100799). In addition to the viral particles, you will also receive purified pAAV-TREtight-mTagBFP2-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-syn-FLEX-splitTVA-EGFP-tTA (Addgene# 100798). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only